node1 | node2 | node1 accession | node2 accession | node1 annotation | node2 annotation | score |
AGXT2 | ALDH1A3 | ENSP00000231420 | ENSP00000332256 | alanine--glyoxylate aminotransferase 2; Can metabolize asymmetric dimethylarginine (ADMA) via transamination to alpha-keto-delta-(NN-dimethylguanidino) valeric acid (DMGV). ADMA is a potent inhibitor of nitric-oxide (NO) synthase, and this activity provides mechanism through which the kidney regulates blood pressure | aldehyde dehydrogenase 1 family, member A3; Recognizes as substrates free retinal and cellular retinol-binding protein-bound retinal. Seems to be the key enzyme in the formation of an RA gradient along the dorso-ventral axis during the early eye development and also in the development of the olfactory system (By similarity) | 0.458 |
AGXT2 | ALDH1B1 | ENSP00000231420 | ENSP00000366927 | alanine--glyoxylate aminotransferase 2; Can metabolize asymmetric dimethylarginine (ADMA) via transamination to alpha-keto-delta-(NN-dimethylguanidino) valeric acid (DMGV). ADMA is a potent inhibitor of nitric-oxide (NO) synthase, and this activity provides mechanism through which the kidney regulates blood pressure | aldehyde dehydrogenase 1 family, member B1; ALDHs play a major role in the detoxification of alcohol-derived acetaldehyde. They are involved in the metabolism of corticosteroids, biogenic amines, neurotransmitters, and lipid peroxidation | 0.458 |
AGXT2 | ALDH1L1 | ENSP00000231420 | ENSP00000377083 | alanine--glyoxylate aminotransferase 2; Can metabolize asymmetric dimethylarginine (ADMA) via transamination to alpha-keto-delta-(NN-dimethylguanidino) valeric acid (DMGV). ADMA is a potent inhibitor of nitric-oxide (NO) synthase, and this activity provides mechanism through which the kidney regulates blood pressure | aldehyde dehydrogenase 1 family, member L1 | 0.458 |
AGXT2 | ALDH1L2 | ENSP00000231420 | ENSP00000258494 | alanine--glyoxylate aminotransferase 2; Can metabolize asymmetric dimethylarginine (ADMA) via transamination to alpha-keto-delta-(NN-dimethylguanidino) valeric acid (DMGV). ADMA is a potent inhibitor of nitric-oxide (NO) synthase, and this activity provides mechanism through which the kidney regulates blood pressure | aldehyde dehydrogenase 1 family, member L2 | 0.458 |
AGXT2 | ALDH3A2 | ENSP00000231420 | ENSP00000345774 | alanine--glyoxylate aminotransferase 2; Can metabolize asymmetric dimethylarginine (ADMA) via transamination to alpha-keto-delta-(NN-dimethylguanidino) valeric acid (DMGV). ADMA is a potent inhibitor of nitric-oxide (NO) synthase, and this activity provides mechanism through which the kidney regulates blood pressure | aldehyde dehydrogenase 3 family, member A2; Catalyzes the oxidation of long-chain aliphatic aldehydes to fatty acids. Active on a variety of saturated and unsaturated aliphatic aldehydes between 6 and 24 carbons in length. Responsible for conversion of the sphingosine 1-phosphate (S1P) degradation product hexadecenal to hexadecenoic acid | 0.486 |
AGXT2 | ALDH3B2 | ENSP00000231420 | ENSP00000255084 | alanine--glyoxylate aminotransferase 2; Can metabolize asymmetric dimethylarginine (ADMA) via transamination to alpha-keto-delta-(NN-dimethylguanidino) valeric acid (DMGV). ADMA is a potent inhibitor of nitric-oxide (NO) synthase, and this activity provides mechanism through which the kidney regulates blood pressure | aldehyde dehydrogenase 3 family, member B2 | 0.458 |
AGXT2 | ALDH7A1 | ENSP00000231420 | ENSP00000387123 | alanine--glyoxylate aminotransferase 2; Can metabolize asymmetric dimethylarginine (ADMA) via transamination to alpha-keto-delta-(NN-dimethylguanidino) valeric acid (DMGV). ADMA is a potent inhibitor of nitric-oxide (NO) synthase, and this activity provides mechanism through which the kidney regulates blood pressure | aldehyde dehydrogenase 7 family, member A1; Multifunctional enzyme mediating important protective effects. Metabolizes betaine aldehyde to betaine, an important cellular osmolyte and methyl donor. Protects cells from oxidative stress by metabolizing a number of lipid peroxidation-derived aldehydes. Involved in lysine catabolism | 0.477 |
AGXT2 | ALDH9A1 | ENSP00000231420 | ENSP00000346827 | alanine--glyoxylate aminotransferase 2; Can metabolize asymmetric dimethylarginine (ADMA) via transamination to alpha-keto-delta-(NN-dimethylguanidino) valeric acid (DMGV). ADMA is a potent inhibitor of nitric-oxide (NO) synthase, and this activity provides mechanism through which the kidney regulates blood pressure | aldehyde dehydrogenase 9 family, member A1; Converts gamma-trimethylaminobutyraldehyde into gamma- butyrobetaine. Catalyzes the irreversible oxidation of a broad range of aldehydes to the corresponding acids in an NAD-dependent reaction | 0.492 |
AGXT2 | DAO | ENSP00000231420 | ENSP00000228476 | alanine--glyoxylate aminotransferase 2; Can metabolize asymmetric dimethylarginine (ADMA) via transamination to alpha-keto-delta-(NN-dimethylguanidino) valeric acid (DMGV). ADMA is a potent inhibitor of nitric-oxide (NO) synthase, and this activity provides mechanism through which the kidney regulates blood pressure | D-amino-acid oxidase; Regulates the level of the neuromodulator D-serine in the brain. Has high activity towards D-DOPA and contributes to dopamine synthesis. Could act as a detoxifying agent which removes D-amino acids accumulated during aging. Acts on a variety of D- amino acids with a preference for those having small hydrophobic side chains followed by those bearing polar, aromatic, and basic groups. Does not act on acidic amino acids | 0.825 |
AGXT2 | ENSG00000257767 | ENSP00000231420 | ENSP00000450353 | alanine--glyoxylate aminotransferase 2; Can metabolize asymmetric dimethylarginine (ADMA) via transamination to alpha-keto-delta-(NN-dimethylguanidino) valeric acid (DMGV). ADMA is a potent inhibitor of nitric-oxide (NO) synthase, and this activity provides mechanism through which the kidney regulates blood pressure | Uncharacterized protein | 0.458 |
AGXT2 | ENSG00000269469 | ENSP00000231420 | ENSP00000470318 | alanine--glyoxylate aminotransferase 2; Can metabolize asymmetric dimethylarginine (ADMA) via transamination to alpha-keto-delta-(NN-dimethylguanidino) valeric acid (DMGV). ADMA is a potent inhibitor of nitric-oxide (NO) synthase, and this activity provides mechanism through which the kidney regulates blood pressure | Uncharacterized protein | 0.458 |
AGXT2 | GRHPR | ENSP00000231420 | ENSP00000313432 | alanine--glyoxylate aminotransferase 2; Can metabolize asymmetric dimethylarginine (ADMA) via transamination to alpha-keto-delta-(NN-dimethylguanidino) valeric acid (DMGV). ADMA is a potent inhibitor of nitric-oxide (NO) synthase, and this activity provides mechanism through which the kidney regulates blood pressure | glyoxylate reductase/hydroxypyruvate reductase; Enzyme with hydroxy-pyruvate reductase, glyoxylate reductase and D-glycerate dehydrogenase enzymatic activities. Reduces hydroxypyruvate to D-glycerate, glyoxylate to glycolate oxidizes D-glycerate to hydroxypyruvate | 0.830 |
AGXT2 | HAO1 | ENSP00000231420 | ENSP00000368066 | alanine--glyoxylate aminotransferase 2; Can metabolize asymmetric dimethylarginine (ADMA) via transamination to alpha-keto-delta-(NN-dimethylguanidino) valeric acid (DMGV). ADMA is a potent inhibitor of nitric-oxide (NO) synthase, and this activity provides mechanism through which the kidney regulates blood pressure | hydroxyacid oxidase (glycolate oxidase) 1; Has 2-hydroxyacid oxidase activity. Most active on the 2-carbon substrate glycolate, but is also active on 2-hydroxy fatty acids, with high activity towards 2-hydroxy palmitate and 2- hydroxy octanoate | 0.824 |
AGXT2 | HAO2 | ENSP00000231420 | ENSP00000316339 | alanine--glyoxylate aminotransferase 2; Can metabolize asymmetric dimethylarginine (ADMA) via transamination to alpha-keto-delta-(NN-dimethylguanidino) valeric acid (DMGV). ADMA is a potent inhibitor of nitric-oxide (NO) synthase, and this activity provides mechanism through which the kidney regulates blood pressure | hydroxyacid oxidase 2 (long chain); Catalyzes the oxidation of L-alpha-hydroxy acids as well as, more slowly, that of L-alpha-amino acids | 0.849 |
AGXT2 | HOGA1 | ENSP00000231420 | ENSP00000359680 | alanine--glyoxylate aminotransferase 2; Can metabolize asymmetric dimethylarginine (ADMA) via transamination to alpha-keto-delta-(NN-dimethylguanidino) valeric acid (DMGV). ADMA is a potent inhibitor of nitric-oxide (NO) synthase, and this activity provides mechanism through which the kidney regulates blood pressure | 4-hydroxy-2-oxoglutarate aldolase 1; Catalyzes the final step in the metabolic pathway of hydroxyproline (Probable) | 0.806 |
AGXT2 | IFFO2 | ENSP00000231420 | ENSP00000387941 | alanine--glyoxylate aminotransferase 2; Can metabolize asymmetric dimethylarginine (ADMA) via transamination to alpha-keto-delta-(NN-dimethylguanidino) valeric acid (DMGV). ADMA is a potent inhibitor of nitric-oxide (NO) synthase, and this activity provides mechanism through which the kidney regulates blood pressure | intermediate filament family orphan 2 | 0.458 |
ALDH1A3 | AGXT2 | ENSP00000332256 | ENSP00000231420 | aldehyde dehydrogenase 1 family, member A3; Recognizes as substrates free retinal and cellular retinol-binding protein-bound retinal. Seems to be the key enzyme in the formation of an RA gradient along the dorso-ventral axis during the early eye development and also in the development of the olfactory system (By similarity) | alanine--glyoxylate aminotransferase 2; Can metabolize asymmetric dimethylarginine (ADMA) via transamination to alpha-keto-delta-(NN-dimethylguanidino) valeric acid (DMGV). ADMA is a potent inhibitor of nitric-oxide (NO) synthase, and this activity provides mechanism through which the kidney regulates blood pressure | 0.458 |
ALDH1B1 | AGXT2 | ENSP00000366927 | ENSP00000231420 | aldehyde dehydrogenase 1 family, member B1; ALDHs play a major role in the detoxification of alcohol-derived acetaldehyde. They are involved in the metabolism of corticosteroids, biogenic amines, neurotransmitters, and lipid peroxidation | alanine--glyoxylate aminotransferase 2; Can metabolize asymmetric dimethylarginine (ADMA) via transamination to alpha-keto-delta-(NN-dimethylguanidino) valeric acid (DMGV). ADMA is a potent inhibitor of nitric-oxide (NO) synthase, and this activity provides mechanism through which the kidney regulates blood pressure | 0.458 |
ALDH1L1 | AGXT2 | ENSP00000377083 | ENSP00000231420 | aldehyde dehydrogenase 1 family, member L1 | alanine--glyoxylate aminotransferase 2; Can metabolize asymmetric dimethylarginine (ADMA) via transamination to alpha-keto-delta-(NN-dimethylguanidino) valeric acid (DMGV). ADMA is a potent inhibitor of nitric-oxide (NO) synthase, and this activity provides mechanism through which the kidney regulates blood pressure | 0.458 |
ALDH1L2 | AGXT2 | ENSP00000258494 | ENSP00000231420 | aldehyde dehydrogenase 1 family, member L2 | alanine--glyoxylate aminotransferase 2; Can metabolize asymmetric dimethylarginine (ADMA) via transamination to alpha-keto-delta-(NN-dimethylguanidino) valeric acid (DMGV). ADMA is a potent inhibitor of nitric-oxide (NO) synthase, and this activity provides mechanism through which the kidney regulates blood pressure | 0.458 |